News

Cardiff teases PLK1 inhibitor efficacy in colorectal cancer ahead of first-line readout

Cardiff Oncology’s PLK1 inhibitor showed hints of efficacy in a shelved Phase II test in second-line colorectal cancer, boosting Cardiff’s share price ahead of an upcoming readout in the frontline setting. The deprioritized ONSEMBLE trial […]